Shots:
- Five-year data from P-III MURANO trial shows sustained PFS with Venclexta/Venclyxto + MabThera/Rituxan vs BR in patients with r/r CLL
- The data showed a reduction in the risk of disease progression or death by 81%, m-OS (82.1% vs 62.2%), patients who completed 2yrs. of treatment without the progressive disease, 63.8% had uMRD
- The P-III CLL14 study also confirms the potential of MRD measurements to predict future outcomes for people with prior untreated CLL who were treated with fixed-duration Venclexta/Venclyxto + Gazyva/Gazyvaro vs Gazyva/Gazyvaro + chlorambucil
Click here to read full press release/ article | Ref: Roche | Image: Fierce Pharma
The post Roche Reports Long-Term Benefits of Venclexta/Venclyxto Based Combination for R/R Chronic Lymphocytic Leukemia first appeared on PharmaShots.
